UCB Showcases Latest Insights on Newly Launched gMG Portfolio at EAN Congress

UCB, a global biopharmaceutical company, has unveiled new research findings supporting its recently launched treatments in the generalized myasthenia gravis (gMG) portfolio. These findings will be presented at the 10th Congress of the European Academy of Neurology (EAN) from June 29 to July 2, 2024, in Helsinki, Finland.

The presentations at EAN will feature a total of 7 abstracts, including 5 e-presentations, showcasing data from studies on UCB’s newly approved medicines for gMG, RYSTIGGO®▼ and ZILBRYSQ®▼. These include insights from real-world studies on clinical outcomes and patient experiences with gMG.

Key highlights of UCB’s scientific and real-world data at EAN include:

  • Post hoc and open-label extension analyses from the pivotal Phase 3 MycarinG study for rozanolixizumab, focusing on long-term safety and patient-reported outcomes such as physical fatigue in adult gMG patients.
  • RAISE XT trials for zilucoplan, featuring e-presentations on the long-term safety and efficacy of zilucoplan in gMG over 96 weeks, as well as a post hoc analysis on long-term response rates over 60 weeks.
  • Posters providing new insights into various aspects of MG, reflecting UCB’s ongoing commitment to understanding the patient experience of the disease.

Donatello Crocetta, Head of Global Rare Disease & Rare Medical at UCB, emphasized, “The insights presented at this year’s EAN congress underscore our commitment to understanding the impact of myasthenia gravis from the patient’s perspective. These analyses from the Phase 3 and Open-Label Extension MycarinG and RAISE XT studies provide clinicians with additional evidence supporting the role of these new treatments in long-term disease management and patient outcomes.”

Manuela Maronati, Head of Europe, Rare Disease at UCB, noted, “EAN coincides with MG Awareness Month, highlighting the challenges faced by those with myasthenia gravis. It underscores the urgency to address the disease and treatment burden, and the impact on daily life and employment.”

During EAN 2024, UCB will host an exhibition showcasing its neurology heritage and portfolio of medicines for epilepsy and gMG. Additionally, UCB has arranged scientific and therapeutic updates for registered healthcare professionals. Visit booth E19 for more information.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter